Literature DB >> 30249495

Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.

Rita Fuerst1, Jun Yong Choi2, Anna M Knapinska3, Lyndsay Smith3, Michael D Cameron4, Claudia Ruiz4, Gregg B Fields3, William R Roush5.   

Abstract

A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhibitor 2, compound 31 was identified which exhibited microsomal half-life higher than 20 min, kinetic solubility higher than 20 μM, and a permeability coefficient greater than 20 × 10-6 cm/s. Compound 31 also showed excellent in vivo PK properties after IV dosing (Cmax = 56.8 μM, T1/2 (plasma) = 3.0 h, Cl = 0.23 mL/min/kg) and thus is a suitable candidate for in vivo efficacy studies in an OA animal model.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  In vitro and in vivo pharmacokinetics; Matrix metalloproteinase 13; Microsomal stability; Permeability; Solubility; Structure-activity relationship; Structure-property relationship

Mesh:

Substances:

Year:  2018        PMID: 30249495      PMCID: PMC6379921          DOI: 10.1016/j.bmc.2018.08.020

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  40 in total

1.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

2.  Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

Authors:  Lawrence A Reiter; Kevin D Freeman-Cook; Christopher S Jones; Gary J Martinelli; Amy S Antipas; Martin A Berliner; Kaushik Datta; James T Downs; James D Eskra; Michael D Forman; Elaine M Greer; Roberto Guzman; Joel R Hardink; Fouad Janat; Nandell F Keene; Ellen R Laird; Jennifer L Liras; Lori L Lopresti-Morrow; Peter G Mitchell; Jayvardhan Pandit; Donald Robertson; Diana Sperger; Marcie L Vaughn-Bowser; Darra M Waller; Sue A Yocum
Journal:  Bioorg Med Chem Lett       Date:  2006-08-30       Impact factor: 2.823

Review 3.  Interstitial collagen catabolism.

Authors:  Gregg B Fields
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

Review 4.  Electrophilic intermediates produced by bioactivation of furan.

Authors:  Lisa A Peterson
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

Review 5.  Metabolic activation and drug toxicity.

Authors:  S D Nelson
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

6.  Structural basis for the highly selective inhibition of MMP-13.

Authors:  Christian K Engel; Bernard Pirard; Sandra Schimanski; Reinhard Kirsch; Jörg Habermann; Otmar Klingler; Volkhard Schlotte; Klaus Ulrich Weithmann; K Ulrich Wendt
Journal:  Chem Biol       Date:  2005-02

Review 7.  Joint diseases and matrix metalloproteinases: a role for MMP-13.

Authors:  Hironari Takaishi; Tokuhiro Kimura; Seema Dalal; Yasunori Okada; Jeanine D'Armiento
Journal:  Curr Pharm Biotechnol       Date:  2008-02       Impact factor: 2.837

8.  Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening.

Authors:  Franck Madoux; Xiaolin Li; Peter Chase; Gina Zastrow; Michael D Cameron; Juliana J Conkright; Patrick R Griffin; Scott Thacher; Peter Hodder
Journal:  Mol Pharmacol       Date:  2008-03-11       Impact factor: 4.436

9.  Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.

Authors:  Lata T Gooljarsingh; Ami Lakdawala; Frank Coppo; Lusong Luo; Gregg B Fields; Peter J Tummino; Richard R Gontarek
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

10.  Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.

Authors:  Hiroshi Nara; Kenjiro Sato; Takako Naito; Hideyuki Mototani; Hideyuki Oki; Yoshio Yamamoto; Haruhiko Kuno; Takashi Santou; Naoyuki Kanzaki; Jun Terauchi; Osamu Uchikawa; Masakuni Kori
Journal:  Bioorg Med Chem       Date:  2014-08-07       Impact factor: 3.641

View more
  7 in total

Review 1.  Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis.

Authors:  Shun Li; David Mark Pritchard; Lu-Gang Yu
Journal:  Cancers (Basel)       Date:  2022-07-03       Impact factor: 6.575

2.  Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia.

Authors:  Takashi Goi; Tatsuo Nakajima; Yoshiyuki Komatsu; Atsushi Kawata; Shuhei Yamakoshi; Okimasa Okada; Masakatsu Sugahara; Asami Umeda; Yoko Takada; Jun Murakami; Rikiya Ohashi; Tomoko Watanabe; Koichi Fukase
Journal:  ACS Med Chem Lett       Date:  2020-06-04       Impact factor: 4.345

3.  Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.

Authors:  Chen Hao Lo; Gemma Shay; Jeremy J McGuire; Tao Li; Kenneth H Shain; Jun Yong Choi; Rita Fuerst; William R Roush; Anna M Knapinska; Gregg B Fields; Conor C Lynch
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 12.701

4.  Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.

Authors:  Anna M Knapinska; Chandani Singh; Gary Drotleff; Daniela Blanco; Cedric Chai; Jason Schwab; Anu Herd; Gregg B Fields
Journal:  ChemMedChem       Date:  2021-01-26       Impact factor: 3.466

5.  Synthesis and exploration of a novel chlorobenzylated 2-aminothiazole-phenyltriazole hybrid as migratory inhibitor of B16F10 in melanoma cells.

Authors:  Muhammad Athar Abbasi; Seon-Mi Yu; Sabahat Zahra Siddiqui; Song Ja Kim; Hussain Raza; Mubashir Hassan; Abdul Rehman Sadiq Butt; Syed Anan Ali Shah; Sung-Yum Seo
Journal:  Toxicol Rep       Date:  2019-08-26

Review 6.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Authors:  Gregg B Fields
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

7.  Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Kalyan Nagulapalli Venkata; Mostafa E Rateb; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.